Asset Management One Co. Ltd. Has $56.11 Million Stake in Medtronic PLC $MDT

Asset Management One Co. Ltd. raised its position in Medtronic PLC (NYSE:MDT) by 2.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 589,186 shares of the medical technology company’s stock after acquiring an additional 13,594 shares during the quarter. Asset Management One Co. Ltd.’s holdings in Medtronic were worth $56,114,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of MDT. Gateway Investment Advisers LLC lifted its stake in Medtronic by 1.6% in the 3rd quarter. Gateway Investment Advisers LLC now owns 90,237 shares of the medical technology company’s stock valued at $8,594,000 after purchasing an additional 1,405 shares during the last quarter. DMKC Advisory Services LLC increased its position in Medtronic by 0.9% during the third quarter. DMKC Advisory Services LLC now owns 24,230 shares of the medical technology company’s stock worth $2,308,000 after buying an additional 208 shares during the last quarter. Moss Adams Wealth Advisors LLC raised its stake in Medtronic by 3.4% in the third quarter. Moss Adams Wealth Advisors LLC now owns 4,431 shares of the medical technology company’s stock valued at $425,000 after buying an additional 147 shares during the period. Saxony Capital Management LLC raised its stake in Medtronic by 3.8% in the third quarter. Saxony Capital Management LLC now owns 3,046 shares of the medical technology company’s stock valued at $290,000 after buying an additional 112 shares during the period. Finally, Global Retirement Partners LLC lifted its position in shares of Medtronic by 17.1% in the third quarter. Global Retirement Partners LLC now owns 33,584 shares of the medical technology company’s stock valued at $3,199,000 after buying an additional 4,900 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Medtronic Price Performance

Medtronic stock opened at $96.03 on Friday. The firm has a market cap of $123.11 billion, a PE ratio of 25.88, a price-to-earnings-growth ratio of 2.53 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. The stock’s fifty day moving average price is $97.65 and its two-hundred day moving average price is $94.07. Medtronic PLC has a one year low of $79.55 and a one year high of $106.33.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The firm had revenue of $8.96 billion during the quarter, compared to the consensus estimate of $8.86 billion. During the same period in the prior year, the company posted $1.26 EPS. The company’s revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts expect that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be issued a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Friday, December 26th. Medtronic’s dividend payout ratio (DPR) is currently 76.55%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Barclays increased their price objective on shares of Medtronic from $109.00 to $111.00 and gave the company an “overweight” rating in a research report on Thursday, November 20th. The Goldman Sachs Group set a $111.00 price target on shares of Medtronic and gave the company a “neutral” rating in a report on Wednesday, November 19th. Wells Fargo & Company boosted their price objective on Medtronic from $100.00 to $114.00 and gave the stock an “overweight” rating in a report on Wednesday, November 19th. Sanford C. Bernstein set a $111.00 target price on Medtronic in a research report on Wednesday, November 19th. Finally, JPMorgan Chase & Co. lifted their price target on Medtronic from $90.00 to $100.00 and gave the stock a “neutral” rating in a report on Thursday, November 13th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $109.94.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).